On March 24, 2021 Onxeo S.A. (Euronext Growth: ALONX; Nasdaq First North: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), in particular against rare or resistant cancers, reported its new dates for the publication of its 2020 annual results and the holding of its annual general meeting (Press release, Onxeo, MAR 24, 2021, View Source [SID1234577072]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Due to the rights issue that is ongoing until March 31, 2021, the publication of the 2020 annual results will take place on April 21, 2021 after market close and the annual general meeting will be held on June 10, 2021. The date for the publication of the 2021 half-year results, scheduled for July 28 after market close, remains unchanged.